Diligence memo · auto-generated · as of July 2, 2026
Hollister Biosciences Inc.
Hollister Biosciences Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Hollister Biosciences Inc. operates in Biotech / Pharma, based in HOLLISTER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Hollister Biosciences Inc. has raised $14M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.8M on 2020-03-24.
Most recent recorded round closed around 2021-03-02.
Valuation (modeled)modeled
Provath models Hollister Biosciences Inc. at approximately $21M (range $964K–$99M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.13× the median modeled value of Series A Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 5.3 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: Advanced Bio Development, Inc., Generian Pharmaceuticals, Inc., Teiko Bio, Inc., Singular Bio, Inc., Genomic Prediction, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.